摘要
目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003年5月至2011年11月期间D+/R+同种异体肾移植患者93例,肾移植术后预防性应用更昔洛韦,对移植后1年内巨细胞病毒的感染率、感染发生的时间及有症状的CMV发病率进行以及用药后不良事件进行分析。结果:在D+/R+肾移植人群中预防性使用更昔洛韦后的感染率为28%,有症状的CMV发病率4.3%,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1%。结论:在D+/R+肾移植术后患者中预防性更昔洛韦能够预防CMV感染并且延长CMV初次感染时间,使D+/R+肾移植患者获益。
Objective： To assess the efficacy and tolerability of ganciclovir to prevent cytomegalovirus（CMV）infection after renal transplantation. Methods： 93 D＋/R＋ renal allograft recipients were given Prophylactic treatment of ganciclovir, and the incidence of CMV infection and the time of infection and adverse event in 1year was observed. Results： In D＋/R＋ renal allograft recipients who were received ganciclovir prophylaxis, the incidence of CMV infection were 28 %, and the time to first viremia was 231.3 d. The incidence of serious adverse events was 45.1 %. Conclusions： Ganciclovir prophylaxis significantly reduces CMV infection in D＋/R＋ renal allograft recipients. However, it needs further studies in RCT.
出处
《现代生物医学进展》
CAS
2016年第5期891-893,897,共4页
Progress in Modern Biomedicine
关键词
肾移植
巨细胞病毒
更昔洛韦
预防性用药
Kidney transplantation
Cytomegalovirus
Valganciclovir
Prophylaxis
